

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0054
Drug name and formulations:		Vitaros® cream (alprostadil 3mg/g cream)
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Relatively safe. Reports of local adverse effects in partner. Safer than PDE5 inhibitors in individuals on long term daily nitrates.
Clinical effectiveness	<i>Established licensed product</i>	40% of PDE5 failures get benefit from this treatment.
Strength of evidence		No head to head comparison, anecdotal evidence that it is better than MUSE®.
Cost effectiveness or resource impact	£	Significantly more expensive than PDE5 inhibitors. Less expensive than the injections.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	Second line for PDE5 failures or patients on long term nitrates.
National guidance and priorities	<i>NICE, MTRAC</i>	NHSE- not a high priority.
Local health priorities	<i>CCG views</i>	CCGs did not see as a priority.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	None required.

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Approved as AMBER, for patients who would otherwise use alprostadil injection. <u>Specialist initiation.</u>
Implementation requirements:	
Implementation monitoring:	